Channel Therapeutics Files 8-K

TL;DR

Channel Therapeutics filed an 8-K on May 1st, reporting financials and exhibits.

AI Summary

Channel Therapeutics Corp. (formerly Chromocell Therapeutics Corp.) filed an 8-K on May 1, 2025, reporting on financial statements and exhibits. The company, incorporated in Nevada, is involved in the Biological Products sector. Its principal executive office is located at 4400 Route 9 South, Suite 1000, Freehold, NJ 07728.

Why It Matters

This filing provides an update on Channel Therapeutics Corp.'s regulatory and financial reporting, which is crucial for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This is a routine filing of financial statements and exhibits, not indicating any significant operational or financial changes.

Key Players & Entities

• Channel Therapeutics Corp. (company) — Registrant
• Chromocell Therapeutics Corp. (company) — Former company name
• May 1, 2025 (date) — Date of earliest event reported
• Nevada (jurisdiction) — State of incorporation
• 4400 Route 9 South, Suite 1000, Freehold, NJ 07728 (address) — Registrant's principal executive office
• (877) 265-8266 (phone_number) — Registrant's telephone number

FAQ

From the Filing

0001753926-25-000722.txt : 20250501 0001753926-25-000722.hdr.sgml : 20250501 20250501170554 ACCESSION NUMBER: 0001753926-25-000722 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250501 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250501 DATE AS OF CHANGE: 20250501 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Channel Therapeutics Corp CENTRAL INDEX KEY: 0001919246 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 863335449 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41964 FILM NUMBER: 25904249 BUSINESS ADDRESS: STREET 1: 685 US HIGHWAY ONE CITY: NORTH BRUNSWICK STATE: NJ ZIP: 08902 BUSINESS PHONE: 9176446313 MAIL ADDRESS: STREET 1: 685 US HIGHWAY ONE CITY: NORTH BRUNSWICK STATE: NJ ZIP: 08902 FORMER COMPANY: FORMER CONFORMED NAME: Chromocell Therapeutics Corp DATE OF NAME CHANGE: 20220323 8-K 1 g084795_8k.htm 8-K false 0001919246 0001919246 2025-05-01 2025-05-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): May 1, 2025   Channel Therapeutics Corporation (Exact name of registrant as specified in its charter)   Nevada   001-41964   86-3335449 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   4400 Route 9 South , Suite 1000 Freehold , NJ   07728 (Address of registrant’s principal executive office)   (Zip code)   Registrant’s telephone number, including area code: (877) 265-8266   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   CHRO   The NYSE American LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐         Item 7.01. Regulation FD Disclosure.   In accordance with Sections 401(h) and 610(b) of the NYSE American LLC Company Guide, a company listed on the NYSE American LLC that receives an audit opinion that contains a going concern emphasis or qualification must make a contemporaneous public announcement through the news media disclosing the receipt of such qualified opinion. The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission on March 27, 2025, contains